MYRIAD GENETICS, INC. Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale
MYRIAD GENETICS, INC. (MYGN) reported Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale · last filed 2022-02-25
- MYRIAD GENETICS, INC. other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2021 was $0.00.
- MYRIAD GENETICS, INC. other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2020 was $0.00.
- MYRIAD GENETICS, INC. other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2019 was $0.00.
- MYRIAD GENETICS, INC. other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2018 was $0.00.
| Period end | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 6 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 12 month |
|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-25 | |
| 2020-12-31 | $0.00 10-K · filed 2022-02-25 | |
| 2020-06-30 | $0.00 10-K · filed 2022-02-25 | |
| 2019-06-30 | $0.00 10-K · filed 2022-02-25 | |
| 2018-06-30 | $0.00 10-KT · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |